title: Antimalarial drug discovery - the path towards eradication.
abstract: Malaria is a disease that still affects a significant proportion of the global human population. Whilst advances have been made in lowering the numbers of cases and deaths, it is clear that a strategy based solely on disease control year on year, without reducing transmission and ultimately eradicating the parasite, is unsustainable. This article highlights the current mainstay treatments alongside a selection of emerging new clinical molecules from the portfolio of Medicines for Malaria Venture (MMV) and our partners. In each case, the key highlights from each research phase are described to demonstrate how these new potential medicines were discovered. Given the increased focus of the community on eradicating the disease, the strategy for next generation combination medicines that will provide such potential is explained.
authors.affiliation: Medicines for Malaria Venture, ICC, 20 Route de Pré-Bois - PO Box 1826, 1215 Geneva 15, Switzerland.
authors.forename: Jeremy N
authors.initials: JN
authors.lastname: Burrows
authors.affiliation: Medicines for Malaria Venture, ICC, 20 Route de Pré-Bois - PO Box 1826, 1215 Geneva 15, Switzerland.
authors.forename: Emilie
authors.initials: E
authors.lastname: Burlot
authors.affiliation: Medicines for Malaria Venture, ICC, 20 Route de Pré-Bois - PO Box 1826, 1215 Geneva 15, Switzerland.
authors.forename: Brice
authors.initials: B
authors.lastname: Campo
authors.affiliation: Medicines for Malaria Venture, ICC, 20 Route de Pré-Bois - PO Box 1826, 1215 Geneva 15, Switzerland.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Cherbuin
authors.affiliation: Medicines for Malaria Venture, ICC, 20 Route de Pré-Bois - PO Box 1826, 1215 Geneva 15, Switzerland.
authors.forename: Sarah
authors.initials: S
authors.lastname: Jeanneret
authors.affiliation: Medicines for Malaria Venture, ICC, 20 Route de Pré-Bois - PO Box 1826, 1215 Geneva 15, Switzerland.
authors.forename: Didier
authors.initials: D
authors.lastname: Leroy
authors.affiliation: Medicines for Malaria Venture, ICC, 20 Route de Pré-Bois - PO Box 1826, 1215 Geneva 15, Switzerland.
authors.forename: Thomas
authors.initials: T
authors.lastname: Spangenberg
authors.affiliation: Medicines for Malaria Venture, ICC, 20 Route de Pré-Bois - PO Box 1826, 1215 Geneva 15, Switzerland.
authors.forename: David
authors.initials: D
authors.lastname: Waterson
authors.affiliation: Medicines for Malaria Venture, ICC, 20 Route de Pré-Bois - PO Box 1826, 1215 Geneva 15, Switzerland.
authors.forename: Timothy Nc
authors.initials: TN
authors.lastname: Wells
authors.affiliation: Medicines for Malaria Venture, ICC, 20 Route de Pré-Bois - PO Box 1826, 1215 Geneva 15, Switzerland.
authors.forename: Paul
authors.initials: P
authors.lastname: Willis
mesh_terms: D000962:Antimalarials / Q000138:chemical synthesis / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D060740:Disease Eradication; D004338:Drug Combinations; D015195:Drug Design; D055808:Drug Discovery; D006801:Humans; D008018:Life Cycle Stages / Q000187:drug effects*; D008288:Malaria / Q000188:drug therapy* / Q000469:parasitology / Q000517:prevention & control; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D010966:Plasmodium vivax / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D000962:Antimalarials; D004338:Drug Combinations